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Abstract 
Since its discovery in 1922, vitamin E has been widely investigated for its role as a 
powerful, chain-breaking antioxidant that is required for human health. However, some 
basic issues still remain unclear, such as the mechanism and dynamics of the intracellular 
trafficking of a-tocopherol. To better understand tocopherol's biological activity at the 
cellular level, fluorescence spectroscopy and microscopy have been found to be valuable 
tools. 
This thesis reports the synthesis of a new fluorescent analogue of a-tocopherol, a-
tocohexaenol, an intrinsically fluorescent analogue of a-tocopherol. Different 
methodologies of preparation have been attempted and a strategy using a preformed 
chromanol head plus C lO and Cs portion of the polyene side chain finally provided us the 
desired a-tocohexaenol. a-Tocohexaenol shows a strong fluorescence in both ethanol and 
hexanes with maximum Aab = 368 nm and maximum /...em = 521 nm. This compound is 
stable for a couple of weeks in ethanol or hexane solution if stored at 0 °C and protected 
form light. It decomposes slowly at room temperature and light will accelerate its 
decomposition (within 5 hours). Thus, a-Tocohexaenol may be a useful fluorescent probe 
to study the biochemistry and cell biology of vitamin E. 
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1. Introduction 
1.1 Discovery and Structure of Vitamin E 
The vitamins are a group of compounds that are required in the diet in small amounts for 
the maintenance of normal health and metabolic integrity. Vitamin E was discovered in 
1922 by Herbert Evans and Katherine Bishop in green leafy vegetables. 1 In 1924 Barnett 
Sure named it vitamin E.2 It was scientifically named tocopherol because vitamin E 
supported fertility. This word comes from the Greek word takas which means childbirth, 
and phera meaning to bring birth, and the al referring to the alcohol properties of this 
molecule. At present vitamin E is regarded as a generic name for four tocopherols and 
four tocotrienols that have the following general structural features: an aromatic 
chromanol head and a 16-carbon hydrocarbon tail. The difference between tocopherols 
and tocotrienols is that tocopherol has a saturated side chain derived from 
phytyldiphosphate (PDP), while tocotrienol has an unsaturated isoprenoid side chain 
derived from geranylgeranyldiphosphate (GGDP).3 Tocopherols and tocotrienols are 
further separated into individual compounds assigned by prefix a, ~, y, D, depending on 
the number and position of methyl substitution on the chromanol ring (Figure 1). 
1 
Tocopherol 
Tocotrienol 
Rl R2 
u-Tocopherolffocotrienol CH3 CH3 
~-Tocopherolffocotrienol CH3 H 
y-Tocopherolffocotrienol H CH3 
8-Tocopherolffocotrienol H H 
Figure 1. Chemical structures of tocopherols and tocotrienols. 
Vitamin E is an essential component of the human diet and is synthesized exclusively by 
photosynthetic organisms.3 Tocopherols are present in vegetable oils and in the germ of 
cereal seeds, whereas tocotrienols are the primary form of vitamin E in the seed 
endosperm of most monocots, including cereal grains such as wheat, rice, barley, and 
palm oil. Vitamin E vitamers have different bioactivity as shown in Table 1.4, 5 The 
biological activity of the major forms of vitamin E are based upon the 'fetal resorption-
gestation' method in rats, an assay that determines the ability of various forms of vitamin 
2 
E to maintain live fetuses in pregnant rats.6 a-Tocopherol was established as the most 
active tocopherol in preventing the death of rat embryos. 
Fetal Resorption Bioassay 
IU/mg Relative Activity Binding to a-TTP 
D-a-tocopherol (RRR) 
D-~-tocopherol (RRR) 
D-y-tocopherol (RRR) 
D-8-tocopherol (RRR) 
D- a-tocotrienol 
D- ~-tocotrienol 
D- y-tocotrienol 
D- 8-tocotrienol 
1.36 
0.75 
0.15 
0.05 
0.75 
0.08 
1.0 
0.50 
0.10 
0.03 
0.50 
0.05 
1.0 
0.38 
0.09 
0.02 
0.12 
Table 1. Relative biological activity7 and affinity to a-TTP (a-tocopherol transfer 
protein) of tocopherols and tocotrienols (all racemic a-tocopherol acetate = 1 IU/mg).4 
1.2 Biosynthesis of Tocopherols and Tocotrienols 
Tocopherols and tocotrienols are synthesized in plants via two converging pathways as 
shown in Figure 2.8-10 The aromatic part of the chromanol ring is derived from the 
precursor homogentisic acid that is formed by p-hydroxyphenylpyruvate dioxygenase 
(HPD) catalyzed oxygenation of p-hydroxyphenylpyruvate, a tyrosine metabolite. HPD 
catalyzes the most complex reaction in the pathway: oxidative decarboxylation of the 
pyruvate side chain to acetate; 1,2-rnigration of the acetate chain; and hydroxylation of C-
1 of the aromatic ring to yield the homogentisic acid. 1 1 The second ring of the chromanol 
head (the pyran) is partly derived from the side chain. 
3 
The prenyl side chain is formed from the condensation of dimethylallylpyrophosphate 
(DMAPP) and three units of IPP to form geranylgeranylpyrophosphate (GGPP). GGPP is 
reduced to phytylpyrophosphate by GGPP reductase. 12 Homogentisate and 
phytylpyrophosphate are fused together by homogentisate prenyltransferase (HPT) to 
give 2-methyl-6-phytylplastoquinone, the common precursor to all tocopherols. 13, 14 
Addition of the saturated phytyl chain leads to tocopherols, addition of the unsaturated 
chain leads to tocotrienols. 15 2-Methyl-6-phytylplastoquinone can directly be cyclized by 
tocopherol cyclase to yield 8-tocopherol. l6 The transfer of a methyl group from S-
adenosylmethionine to the 3-position of the aromatic ring yields 2,3-dimethyl-6-
phytylplastoquinone, which is cyclized to yield 'Y-tocopherol. Final transfer of a methyl 
group to the 5-position of the chromanol ring catalyzed by 'Y-tocopherol methyl 
transferase converts 'Y- and 8-tocopherol into a- and ~-toxcopherol respectively.17 
Tocotrienols are formed by a corresponding pathway.8, 15 
1.3 Absorption and Transport of Vitamin E 
All forms of vitamin E are absorbed as the free phenol form by the intestine without 
discrimination of the individual isomers.18 The esterified forms of a-tocopherol that are 
commonly present in dietary supplements are hydrolyzed by the pancreatic carboxyl ester 
hydrolase in the intestine before absorption. 19, 20 The absorption of vitamin E is relatively 
poor, only 20% to 40% of a dose is normally absorbed from the small intestine. 19, 21 
4 
HO~l ~H2 
~C02H 
tyrosine j tyrosine 
aminotransferase 
I 0 HODJ 
.# C02H 
p-hydroxylphenyl 
pyruvate 
HP;\ O2 
LJ \-- CO2 
HO'()~ 
l~~OH 
C02H 
homogentisic 
acid 
PPO 
+ 
PPO~ 
IPP 
+ PPO~ 
DMAPP 
PPO 
# 
geranylgeranylpyrophosphate 
phytylpyrophosphate 
HPTIHGGT l !~C02 
HO 
2-methyl-6-phytyl plastoquinone 
SAM/methyl 
/ transferase 
"m! 
2,3-dimethyl-6-phytyl 
plastoquinone 
tocopherol 
cyclase 
.. 
HO 
R 
~OPh""l oyd", 
HO 
R 
j y-TMT 
y-tocopherol (R = CH3) 
8-tocopherol (R = H) 
a-tocopherol (R = CH3) 
~-tocopherol (R = H) 
Figure 2. Biosynthesis of tocopherols and tocotrienols (IPP-isopentenyl pyrophosphate; DMAPP-
dimethylallylpyrophosphate; HPD-p-hydroxyphenylpyruvate dioxygenase; GGPP-geranylgeranylpyrophosphate; HPT-
homogentisate prenyltransferase; HGGT-homogentisate geranylgeranyl transferase; SAM-S-adenosylmethionine; 
TMT-methyltransferase).8 
5 
In intestinal mucosal cells, all vitamers of vitamin E are incorporated into chylomicrons, 
and chylomicron remnants are then taken up by the liver.22 The liver is a major storage 
site of a-tocopherol, accounting for one-third of the total body content of a-tocopherol.23 
Chylomicron pathway is thought to be predominant for vitamin E absorption in the 
intestine.24 However, an alternative pathway for vitamin E absorption via HDL efflux 
was also suggested by the improvement of vitamin E deficiency due to the use of high 
dose supplementation in chylomicron-dificient patients?4 This HDL-dependent 
mechanism has been characterized by Anwar et al. in CaCo2 cells.25 
a-Tocopherol, which binds to the liver a-tocopherol transfer protein (a-TTP), is then 
exported in very low-density lipoprotein (VLDL) and is available for tissue uptake.26 
Later it appears in low-density lipoprotein (LDL) and high-density lipoproteinm (HDL) 
as a result of metabolism of VLDL in the circulation. The other vitamers, which do not 
bind well to a-TTP are not incorporated into VLDL;27,28 they are metabolized in the liver 
and excreted. 
Lipoproteins are the major carriers of vitamin E. Both LDL and HDL are important 
sources of vitamin E for cellular uptake.24 Two mechanisms were suggested for the tissue 
uptake of vitamin E: lipoprotein lipase releases some of the vitamin E from the 
chylomicron structure by hydrolyzing the triacylglycerol in chylomicrons and VLDL, 
whereas separately there is receptor-mediated uptake of LDL-bound vitamin E. 
Mardones' study suggested that the main mechanism for tissue uptake of vitamin E from 
plasma lipoprotein is by way of scavenger receptor class B type I (SR-BI).29 
The binding activity of a-TTP in rat liver cytosol was first reported by Catignani in 
1975.30 In 1995 Arita et aI. cloned the human transcript encoding TTP?l It is generally 
6 
accepted that by facilitating the secretion of a-tocopherol from hepatocytes to 
lipoproteins TTP functions as a key regulator of vitamin E status.32 The affinity of a-TTP 
for the vitamers varies: a-tocopherol shows the highest affinity, followed by ~-, 'Y-, and 8-
tocopherol.28 How a-TTP mediates the secretion of a-tocopherol into VLDL is not fully 
understood. It has been hypothesized that the role of a-TTP is not in the secretion, but in 
the cytosolic transport of a-tocopherol from late endosome to the plasma membrane?3 
In liver the metabolism of vitamin E is initiated by cytochrome P450 (CYP450). The ro-
oxidation that is the hydroxylation of the ro-methyl group is followed by the removal of 
carbon units by ~-oxidation. 34 Different isoforms of CYP450 enzymes have been 
suggested to be responsible for the metabolism. The cytochrome P450 isoform CYP4F2 
catalyzes tocopherols other than RRR-a-tocopherol into water-soluble products that are 
excreted in urine?5 Figure 3 shows the final products of tocopherol oxidative 
metabolism: carboxyethyl-hydroxychromans (CEHC), and its intermediates, 
carboxymethylhexyl-hydroxychromans 
hydroxychromans (CMBHC) .34 
GOOH 
u-CMHHC 
GOOH 
a-CMBHC 
Figure 3. Metabolites of a-tocopherol. 
(CMHHC) and carboxymethylbutyl-
GOOH 
7 
a-Tocopherol has the longest half-life in circulation (48 hours); that of B- and y- is only 
of the order of 13 to 15 hours.5 The retention time of a-tocopherol in tissues varies. In the 
lungs the vitamin has a half life of 7.6 days, in liver 9.8 days, in skin 23.4 days, in brain 
29.4 days, and in the spinal cord 76.3 days.36 
1.4 Vitamin E as an Antioxidant 
Polyunsaturated fatty acids undergo oxidative attack by hydroxyl radicals that yield 
alkylperoxyl radicals after reaction with oxygen (Figure 4), which perpetuate a chain 
reaction in the lipid with potentially disastrous consequence for cells.8, 37 The initiating 
step of this chain reaction is the abstraction of a hydrogen atom from the bis-allylic site 
on an unsaturated fatty acid to yield a carbon-centered radical. The hydrogen atom is 
almost invariably abstracted from a bis-allylic methylene carbon. Once the radical is 
formed it immediately reacts with molecular oxygen to form a fatty acid peroxyl radical. 
The fate of the peroxyl radical depends on the following reactions: (A) Encounter with an 
antioxidant such as vitamin E (chain termination). (B) Encounter with another fatty acid 
(chain propagation). (C) Encounter with a double bond in the same molecule to form an 
endoperoxide. (D) Loss of oxygen (~-fragmentation). 
Vitamin E is generally regarded as the most important lipid-soluble antioxidant in blood 
plasma and circulating lipoproteins. It can inhibit lipid peroxidation in biological 
membranes by scavenging the chain-propagating peroxyl radicals as shown in reaction 
(1): 38, 39 
ROO· + Toc-OH -+ ROOH + Toc-O· (1) 
The resultant chromanoxyl radicals could also participate in further propagation of lipid 
peroxidation, which is called pro-oxidation: 
8 
Toc-O· + RH ~ Toc-OH + R (2) 
The LDL particle has a lipid core consisting of neutral lipids (cholesteryl and triglyceride 
esters of polyunsaturated fatty acids, and free cholesterol) and a coat of polar lipids 
(phosphatidy1choline esters of C18:2 and C20:4).8 When LDL is attacked by a peroxyl 
radical, the resulting radical will likely react with a-tocopherol to generate a 
hydroperoxide and the tocopheroxyl radical. Because the life time of this radical is 
sufficiently long (estimated about 12.5 s), it will eventually abstract a hydrogen from a 
bis-allylic methylene from linoleic or arachidonic acid, creating a fatty acid radical and a 
new autoxidation chain reaction.4o This is called a-tocopherol-mediated peroxidation 
(TMP). TMP will cause oxidative damage to lipids especially in the absence of 
coantioxidants such as vitamin C (ascorbate) or ubiquinone.41 , 42 
On the other hand it can be reduced back to vitamin E by reductants, which do not 
propagate lipid peroxidation: 
Toc-O· + AH2 ~ Toc-OH + AH (3) 
The tocopheroxyl radicals can be reduced back to tocopherol by redox-active reagents 
such as vitamin C or ubiquinol.43, 44 In homogeneous solution phase autoxidation, the 
tocopheroxyl radicals will react with a second peroxyl radical to give a non-radical 
product which leads to the destruction of a-tocopherol as an antioxidant.8 
In addition, both a- and y-tocopherol can react with peroxynitrite which comes from the 
reaction between nitric oxide and superoxide (Figure 5). y-Tocopherol is more reactive 
than a-tocopherol and undergoes nitration.45 
9 
Formation of fatty acid peroxyl radical & ~-fragmentation: 
H 
R1~R2 
Chain propagation: 
R1~R2. + 
00 
H 
R3~R4 
----J .. ~ R1~R2 
OOH 
Endoperoxide formation: 
R1~R5 
00 
.. 
R1~R5 
0-0 
Termination of the radical reaction by a-tocopherol: 
Reduced back to a-tocopherol 
vitamin C 
R or ubiquinol 
R 
.. 
___ --i .... R1~R2 
OOH 
R 
Figure 4. Reactions of fatty acid peroxyl radicals.s 
10 
• 
+ R3~R4 
+ 
R 
R 
R 
a-tocopherol a-tocopherolquinone 
ON~ R 
y-tocopherol nitrate 
y-tocopherol 
R 
y-tocopherol orthoquinone 
Figure 5. Reaction of a-tocopherol and y-tocopherol with peroxynitrite.4 
1.5 Therapeutic Potentials of Vitamin E 
1.5.1 Vitamin E Deficiency and Ataxia with Isolated Vitamin E Deficiency 
Vitamin E deficient pregnant female animals suffer fetal resorption. 1 Vitamin E 
deficiency in laboratory animals also leads to muscular dystrophy46 and neurologic 
lesions.47, 48 Combined dietary deficiency of vitamin E and selenium causes fatal 
myopathy.49 
Dietary deficiency of vitamin E is rare in humans, however, patients with severe fat 
malabsorption will develop vitamin E deficiency. Vitamin E deficiency causes severe 
11 
spinocerebellar lesions coupled with low plasma vitamin E levels.5o Patients lacking 
hepatic a-TTP suffer from "ataxia with isolated vitamin E deficiency" (A VED). Traber et 
al. first suggested that there was a connection between A VED and the dysfunctional 
incorporation of a-tocopherol into VLDL in the liver. I8 In 1995 it was established that 
the molecular defects responsible for A VED are mutations in the gene-encoding u-
TTP.50, 51 The extremely low plasma levels of a-tocopherol in AVED patients can be 
elevated by dietary vitamin E supplementation. 18 
Animal models in which the expression of TTP has been disrupted unequivocally 
demonstrate the relationship between vitamin E, normal health, and TTP integrity?2 For 
example, plasma tocopherol levels are very low in TTP-I- mice.52 As TTP-I- mice age, they 
display the neurological symptoms associated with A VED.53 The severe pathologies 
caused by vitamin E deficiency in humans also clearly demonstrated that vitamin E is an 
essential nutrient for human health.32 
1.5.2 Cardiovascular Disease 
The oxidation of biological molecules, such as lipids, proteins and DNA, by molecular 
oxygen, is regarded to be involved in the development of numerous pathological events, 
such as cancer, cardiovascular disease (CVD) and even the aging process. Vitamin E, as a 
chain-breaking antioxidant, will suppress the oxidation and protect biological molecules 
and tissues from oxidative damage. Therefore, consumption of certain foods enriched in 
vitamin E is thought to reduce the incidence of CVD and cancer.54 It was also 
hypothesized that tocopherol might prevent oxidative modification of LDL, a process 
believed to be involved in the formation of atherosclerotic plaque.55 
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There is considerable controversy regarding any beneficial effect of vitamin E in 
preventing CVD,56 but it should be keep in mind that vitamin E supplementation was 
found to be beneficial for certain patients in prevention trials. 57-59 
1.5.3 Cancer 
a-Tocopherol succinate was the first vitamin analogue that demonstrated the ability to 
inhibit the growth of cancer cells.6o This effect has been shown for numerous additional 
cancer cell lines.8, 61 Tocotrienols were shown to inhibit the growth of human breast 
cancer cells in culture.62,63 Fuchs' study shows that the risk of colon cancer for women 
taking folate, through multi-vitamin (including vitamin E) intake for at least 15 years, 
was reduced 75 %.64 
Several mechanisms are thought to be involved in vitamin E's anti-cancer effects: the 
inhibition of lipid peroxidation and the formation of reactive products such as fatty acid 
peroxyl radicals; direct effects on tumor cells such as control of tumor growth through 
induction of differentiation; elimination of tumor cells by increased efficacy of antitumor 
. b h . 8 45 65-67 actIOns y t e Immune system. ' , 
There are also negative reports on the relationship between cancer and vitamin E. In 
Kline's study there is no evidence that vitamin E protects women from breast cancer.68 
Another report suggests that there is no protective effect of a-tocopherol on prostate 
cancer incidence.69 The inconsistent results between clinical studies and epidemiological 
data could arise from using different forms of vitamin E.70 
1.5.4 Cataracts 
There is good evidence that cataracts are the result of oxidative damage to a-crystallin in 
the lens of the eyes, and therefore dietary intakes of antioxidants might be beneficia1.4 
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One study suggested a reduction in the risk of cataracts of at least 50% by taking more 
supplementary vitamins C and E.71 Another study that investigated the effect of vitamin 
E on the development of cataract and age-related maculopathy reported a positive 
result.72 
1.6 Vitamin E: non-antioxidant Functions 
a-Tocopherol inhibits platelet aggregation both 10 vitro and in VIVO, 10 response to 
agonists such as arachidonic aicd and phorbol ester. This seems to be mediated by a 
protein kinase C dependent mechanism.4 Activation of protein kinase C is a key step in 
signal transduction and is involved in cell growth and differentiation.73 Protein kinase C 
can be inhibited by physiologic concentration of a-tocopherol in the medium of a variety 
of cells.74 Inhibition of protein kinase C may also be the mechanism by which u-
tocopherol inhibits vascular smooth muscle proliferation, a factor in thrombus formation 
and platelet aggregation.75-77 
In monocytes, a-tocopherol reduces formation of reactive oxygen species, cell adhesion 
to the endothelium, and release of interleukins and tumor necrosis factor. a-Tocopherol 
inhibits the assembly of the respiratory burst NADPH oxidase that is responsible for 
oxygen radical generation. The effects on cell adhesion are from the inhibition of protein 
kinase C. The effects on cytokine release is from inhibition of 5-lipoxygenase. In 
macrophages, a-tocopherol reduces release of interleukin-1 and the activity of the 
scavenger LDL receptor, which in tum reduces the accumulation of cholesterol and 
transformation into foam cells.78, 79 In experimental animals, vitamin E deficiency 
depresses immune system function, which suggests a signaling role of vitamin E in the 
immune system.80 
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1.7 Tocotrienols: vitamin E beyond tocopherols 
As D-a-(RRR)-tocopherol has the highest biological activity in the vitamin E family; the 
term vitamin E is often used synonymously with a-tocopherol. Compared to a-
tocopherol, the tocotrienols have received much less attention. However, recent studies 
indicate that tocotrienols possess unique biological functions. 81 Although tocopherols and 
tocotrienols share similar structure, the unsaturated side chain of tocotrienols allows for 
more efficient penetration into tissues such as brain and liver. 82 Yoshida et al. reported 
that the corresponding tocopherols and tocotrienols exerted the same reactivity toward 
radicals in solution, but tocotrienols were more readily transferred between the 
membranes and incorporated into membranes than tocopherols.83 a-Tocotrienol showed 
much higher antioxidant potency than a-tocopherol against lipid peroxidation in rat liver 
microsomal membranes; the reasons for this were suggested by Serbinova et al. as 
follows: higher recycling efficiency from chromanoxyl radicals; more uniform 
distribution in membrane bilayer; stronger disordering of membrane lipids which makes 
interaction of chromanols with lipid radicals more efficient.38 
a-Tocotrienol also possesses numerous functions that are not shared by a-tocopherolY 
For example, nanomolar concentration of a-tocotrienol prevents inducible 
neurodegeneration by regulating specific mediators of cell death.84 Tocotrienol 
administration reduces oxidative protein damage and extends the mean life span of C. 
elegans.85 Tocotrienol but not tocopherol suppresses the growth of human breast cancer 
cells.86 
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1.8 Aims & objectives 
Deuterated and radiolabeled compounds have been used in the study of the biological 
activity of vitamin E. However, the study of vitamin E's biokinetics and distribution has 
been impossible at the cellular level because the above-mentioned method requires tissue 
extracts, which lacks the time and spatial resolution to determine the rates of vitamin E 
movement between different pools inside and outside of a cell. So it would be 
advantageous to use a non-destructive technique such as fluorescence spectroscopy-
microscopy. Vitamin E is only weakly fluorescent, therefore in order to use fluorescence 
spectroscopy-microscopy a fluorophore should be attached to the molecule. Using this 
strategy a series of fluorescent analogues of a-tocopherol have been synthesized in our 
lab87 and successfully used in the study of binding with TTP and intracellular trafficking 
of vitamin E.88, 89 Another analogue was synthesized by Oleynik et al. as an off/on 
fluorescent antioxidant indicator (Figure 6) .90 
H 
C9-Nitrobenzoxadiazole-a-tocopherol 
Et 
H 
Et 
C9-Anthroyloxy-a-tocopherol BODIPY -a-tocopherol 
Figure 6. Structure of three fluorescent analogues of a-tocopherol. 
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However such fluorescent analogues of a-tocopherol may also change the structure of the 
a-tocopherol to a degree that affects its ability to act like the natural ligand (a-
tocopherol). For instance, NBD-a-tocopherol is appreciably more water-soluble than a-
tocopherol. A new fluorescent analogue of a-tocopherol was designed and synthesized in 
this thesis (Figure 7). 
Compound 1 a-tocohexaenol 
Figue 7. Structure of a-tocohexaenoll. 
This new molecule, a-tocohexaenol, keeps much of the structure of a-tocopherol: it has 
the same chromanol head and the skeleton of a-tocopherol. The only difference is that six 
conjugated double bonds are introduced to its side chain, which will make it fluorescent. 
In addition, by combing a chromanol head of a-tocopherol and a conjugated polyene 
system similar to carotenoids, it could be a more potent antioxidant itself.91 • 92 This new 
compound is expected to show a fluorescence excitation maximum of 366 nm (calculated 
according to Fieser-Kuhn rules), and an emission maximum of 465 nm. Compared with 
a-tocopherol, which has an excitation maximum of 292 nm and emission maximum of 
325 nm, a-tocohexaenol's fluorescent properties will make it a useful fluorescent reporter 
that is not interfered with by endogenous fluorophores such as tryptohan. 
A great deal of evidence exists to show that a-tocopherol has considerable 
conformational freedom in a phospholipid membrane.93 It may bob up and down to some 
degree; it can rotate about its long axis; and it is able to diffuse within the two-
dimentional fluid of one leaflet of the bilayer.93 We would predict that the trans-polyene 
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tail of a-tocohexaenol will make it more rigid so that it can not have as much 
conformational freedom as a-tocopherol when residing in membranes. Figure 8 is a 
cartoon illustration of a-tocohexaenol in a membrane. Since a-tocopherol will spend 
some time in a fully extended conformation, a-tocohexaenol will mimic the activity of a-
tocopherol to some extent. 
Figure 8. Cartoon illustration of a-tocohexaenol & a-tocopherol in a phospholipid 
membrane. 
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2. Results and Discussions 
2.1 Design of a fluorescent analogue of Vitamin E 
In order to use a non-destructive method such as fluorescence spectroscopy in the study 
of the bioactivity of vitamin E, a suitable analogue is necessary. To design new 
fluorescent analogues of a-tocopherol the following requirements must be considered: 
1) It should disturb the structure of the a-tocopherol as little as possible. 
2) It must have good fluorescent characteristics. 
a-Tocohexaenoll (Figure 8) is considered to meet these requirements and will have a Aabs 
> 300 nm. According to Fieser-Kuhn rules94 the absorption wavelength of this conjugated 
polyene compound can be calculated as follows: 
Amax = 114 + 5 x 25 + 6(48.0 - 1.7 x 6) 
= 366 nm 
Based on the similarity to a comparable system used by Prestwich et al.95 it is expected to 
have a fluorescent emission maximum of 465 nm, which will be distinguishable from the 
background fluorescence of a cell. 
2.2 Synthesis of Compound 1 
2.2.1 u-Tocotrienol as Starting Material 
Since the only difference between our target compound and a-tocotrienol is that the target 
molecule has a conjugated side chain with six double bonds, whereas a-tocotrienol has a 
side chain with three methylene-separated double bonds, starting from a-tocotrienol 
appeared to be a possible choice. a-Tocotrienol is available in gram scale from palm 
kernel oil Tocomin-50® by column chromatographic purification. To introduce a 
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conjugated system to the side chain we have tried several different chemistries. All our 
efforts on converting a-tocotrienol to a-tocohexaenol 1 will be discussed in the following 
section. 
2.2.1.1 Bromination.dehydrobromination Method 
HO 
I TBDMSCI, imidazole 
2 Br2/CCl4 
76 % 
Dehydrobromination 
TBDMSO 
2 
Scheme 1 BrominationJdehydrobromination of a-tocotrienol. 
Br 
Kuklev and Smith96 reported the successfully transformation of 1,4,7 -octatriene 
methylene interrupted cis-double bonds of naturally occurring polyunsaturated fatty acid 
to a polyconjugated 1,3,5,7-octatetraenes using bromination-dehydrobromination. In their 
method the bromination of a-linolenic aicd (ALA) with bromine molecule yielded 
dibromides, then treatment with 1,8-diazabicyc1o[5,4,0]undec-7-ene (DBU) initiated 
didehydrobromination and yielded a mixture of conjugated isomers; base catalyzed cis-
trans isomerization finally yielded the all-trans product (Schme 2). 
The same strategy was tried on a-tocotrienol. First the phenol group of a-tocotrienol was 
protected as the TBDMS ether in the presence of imidazole, then the bromination with 3 
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molar equivalent of bromine molecule in CCl4 successfully transformed the a-tocotrienol 
to its hexabromide product. Unfortunately, treatment with various different bases in 
different solvents including sodium hydride or potassium tert-butoxide in dry THF, n-
butyllithium in dry ether, sodium hydroxide in ethanol, sodium ethoxide in ethanol, and 
silver oxide in ethyl acetate did not give any desired product (for details please see the 
thesis of Gu Fan97). We also tried such extreme conditions as heating the hexabromide 
with potassium hydroxide without solvent but again no product was obtained. This 
method was therefore abandoned. 
2.2.1.2 DDQ Dehydrogenation Method 
DDQ (2,3-dichloro-5,6-dicyano-p-benzoquinone) IS a good hydrogen acceptor in 
dehydrogenations forming double bonds adjacent to conjugated double bonds or aromatic 
rings.98-1OO We hoped that treatment with DDQ would form the more stable conjugated 
system and would be the driving force to dehydrogenate a-tocotrienol. 
HO 
AcO 
Acp/pyridine 
80% 
DDQ dehydrogenation 
Scheme 2 DDQ dehydrogenation route to a-tocohexaenol. 
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Scheme 2 illustrates this DDQ dehydrogenation pathway. The phenol group of a-
tocotrienol was first protected as the acetate ester by treatment with acetic acid anhydride 
in pyridine, then the mixture of acetate ester protected a-tocotrienol and DDQ in toluene 
was heated in a sealed tube for various times. Unfortunately, only starting material was 
recovered (30-50%). When the molar equivalent ofDDQ was increased from 3 to 10, all 
starting material was destroyed and small amounts of products were obtained. Although 
the mass spectrum showed that there was a weak peak of interest (m/z = 458) which 
corresponds to the molecular ion of the desired product, the HPLC analysis of the final 
product showed that it was a complex mixture. More importantly, there was no 
absorption around 360 nm which is the characteristic absorption of six conjugated double 
bonds. Thus this method was abandoned as well. 
2.2.1.3 Allylic-hydroxylation by Selenium Dioxide and Dehydration Method 
Selenium dioxide is used in the allylic hydroxylation of isolated double bonds in straight-
chain hydrocarbons which transform an allylic methylene to an allylic alcohol. 
Considering the difficulty of removing colloidal selenium and the formation of 
organoselenium by-products, M.A. Umbreit and K.B. Sharpless101 suggested a method in 
which tert-butyl hydroperoxide (TBHP) was used as a re-oxidant to reoxidize the reduced 
selenium species to Se02, so the reaction can proceed with catalytic amount of Se02. In 
our experiment the Sharpless method was followed. 
The oxidation reaction went very slowly, even after 48 hours of reaction most starting 
material was recovered (80-90%). When the molar equivalent of TBPH was increased to 
7.2, two polar products were obtained. No big improvement was observed when the 
molar equivalent of TBPH was further increased to 14.4. From the TLC two polar spots 
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other than the starting material were visualized. However, we could not determine their 
structure even with its NMR, IR and MS spectra. Considering its poor yield (-10%), we 
chose another hydroxylation reagent: osmium tetroxide. 
1 AC20/pyridine 
2 Se02 
Dehydration 
AcO 
OH 
4 
OH 
Scheme 3 Allylic-hydroxylationldehydration of a-tocotrienol. 
OH 
2.2.1.4 Osmium Tetroxide Dihydroxylation and Dehydration Method 
Oxidization of an olefin with osmium tetroxide is the most reliable way for cis-
dihydroxylation of a double bond. 102 The reaction of an olefin with a stoichiometric 
quantity of osmium tetroxide in pyridine, followed by reductive hydrolysis, is a common 
procedure. However, in consideration of the high cost and toxicity of osmium tetroxide, 
and the difficult workup procedure when pyridine is used, new procedures using catalytic 
amounts of osmium tetroxide were developed. For example, Hofmann's procedure relies 
on metal chi orates as the stoichiometric oxidant,103 and Milas' procedure relies on 
hydrogen peroxide. 104 However, these two reagents give rise to over-oxidation products 
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(ketols and compounds resulting from cleavage of the C-C bond). To suppress the by-
products, Sharpless developed a procedure that used 0.2 % equivalent of OS04, 1.6 
equivalent of tert-butyl hydroperoxide and 10% equivalent of Et4NOH.105 Unfortunately 
Sharpless' method did not give us any hydroxylation product. Even after 72 hours 
reaction, only starting material was recovered (30-40%). We also tried the procedure 
which used NMO (N-methyl-morpholine-N-Oxide) as the stoichiometric oxidant102 but 
once again no product was obtained except starting material. Sharpless also reported 
negative result with tri- and tetrasubstituted olefins. 106 They found that ole fins which 
failed to react with catalytic OS04 were potent inhibitors of the catalytic process. These 
olefins apparently trapped the osmium by forming an extremely stable osmate ester. That 
probably explained why we did not observe any reaction in our experiments. 
1 A~O/pyridine 
20s0 4/NMO 
Dehydration 
AcO 
5 
Scheme 4 Osmium tertaoxide oxidation/dehydration of a-tocotrienol. 
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Literature reports describing the di-hydroxylation of more than two double bonds are 
rare. There is only one article that reported the successful synthesis of the hydroxyl 
analogue of a-tocopherol. 107 Considering their poor yield (-0.5 %) and the uncertainty of 
the next dehydration step, we chosed to synthesize compound 1 through the multi-step 
synthesis outlined in Scheme 5. 
2.2.2 Synthesis a-Tocohexaenol using Wittig Chemistry 
.# # .# # .# 
il 
Br-
+ 
+ (BubP 
.# # .# # .# 
CHO 
6 7 
il 
Br 
.# # .# # .# 
8 
il 
HO 
.# # .# # .# 
9 
Scheme 5 Retrosynthesis of compound 1 based on the use of phosphonium salt. 
2.2.2.1 Mechanism of Wittig Reaction 
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The Wittig reaction is one of the most important and the most effective methods for 
synthesis of carbon-carbon double bonds. lOS The active reagent in this transformation is 
the phosphorous ylide, which is usually prepared from a triaryl- or trialkylphosphine and 
an alkyl halide followed by deprotonation with a suitable base. The mechanism of the 
Wittig reaction is shown in Scheme 6. First, the nucleophilic attack of the ylide to the 
carbonyl group leads to a betaine. The steric bulk of the ylide influences the 
stereochemical outcome of nucleophilic addition to give a predominance of the cis-
betaine, which then forms the cis-oxaphosphatane. Elimination gives the Z-alkene and 
triphenylphosphine oxide. Carbon-carbon bond rotation of the cis-betaine gives the trans-
betaine, which leads to E-alkene through a trans-oxaphosphatane. However, the existence 
and interconversion of the betaine is still under debate. There is evidence that the 
oxaphosphatanes can be formed directly from the [2+2] cycloaddition of phosphonium 
ylides and carbonyl compounds. 109 
There are three different types of ylides depending on the nature of R2 substitute: 
stabilized ylides, when R2 is a strong electron withdrawing group that stabilizes the 
negative charge on the carbon; semi-stabilized ylides, where R2 is an aryl or alkenyl 
substitute which is less stabilizing; nonstabilized ylides, when R2 is an alkyl substitute 
which do not stabilize the negative charge on the carbon. 
The stereochemistry of the olefination of aldehyde with phosphorous ylide is governed 
basically by the nature of the ylide. Nonstabilized ylides give predominantly Z-alkenes; 
while stabilized ylides give predominantly E-alkenes; semi-stabilized ylides usually give 
a mixture of E and Z isomers. 
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trans-betaine cis-betaine 
trans-oxaphosphatane cis-oxaphosphatane 
(E)-alkene (Z)-alkene 
Scheme 6. Mechanism of Wittig reaction. 1 10 
The stereoselectivity is also influenced by many other factors, such as the ligands at 
phosphorous, the nature of solvent and the presence of metal ions. For example, less 
bulky ligands such as triethyl or tributyl phosphonium salts, favor E-alkene when semi-
stabilized ylides were usedY I, 112 For non-stabilized ylides the stereo selectivity of the 
reaction is largely independent of the solvent polarity.l13 Stabilized ylides can be made 
cis- or trans-selective according to the solvent used in the reaction. Under Boden's 
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conditions (with a catalytic amount of 18-crown-6 ether) the stereochemical result is 
significantly dependent on the type of solvent and the nature of the ylide. 114 In the case of 
Wittig reactions with semi-stabilized ylides, the presence of lithium ion leads to a product 
mixture which is enriched with Z alkene; while when sodium or potassium ions are 
present, the mixture is enriched with E alkene. I IS 
2.2.2.2 Synthesis of Compound 1 using C14 + C1S Strategy 
Compound 1 a-tocohexaenol 
Figure 9. The positions of three additional double bonds in compound 1 as compared to 
a-tocopherol. 
In preparing all-trans a-tocohexaenenol 1, the IE, 5E and 9E double bonds were 
stereoselectively installed through Wittig olefination. Scheme 7 illustrates our first effort 
to synthesize compound 1 using Wittig olefinations. The synthesis of pentaenol 9 was 
reported by Liu and Prestwich.9s We hoped that the pentaenol 9 can be converted to its 
bromide product 8 via a substitution reaction then treated with a trialkyl phosphine to 
give the phosphonium salt 7, which would then be coupled with Trolox aldehyde 6 to 
yield the final product 1. 
The all-trans alcohol 9 was prepared according to Prestwich's method as outlined in 
Scheme 7. Starting from ethyl (E)-3-formylbut-2-enoate, the aldehyde group was first 
protected as an acetal (ethylene glycol, PPTS, benzene, 91 %). Reduction of ester 10 with 
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lithium aluminum hydride at 0 DC afforded alcohol 11 (70 %). The protection of alcohol 
11 as silyl ether 12 (TBDMSCI, imidazole, DMF, rt, 90 %) was followed by deprotection 
of the acetal (p-TsOH, H20, 90%) to give the required aldehyde 13. The resulting 
aldehyde 13 was coupled with allylic diethylphosphonate 14a through Horner-
Wadsworth-Emmons reaction to give all-trans triene ester 15 (84 %). 
The phosphonate esters 14a and 14b were prepared from tiglic acid as outlined in 
Scheme 8. First, the allylic bromination of tiglic methyl ester 20 by NBS in CCl4 gave a 
mixture of bromide 21a and 21b at 2: 1 ratio. The ratio of the two isomers was determined 
by their IH NMR. The vinyl proton of 21a had a chemical shift at 6.93 ppm as a quartet, 
whereas the vinyl proton of 21b had a chemical shift at 7.13 ppm and appeared as a 
triplet. The following Michealis-Arbuzov reaction (Scheme 8) gave a mixture of 14a and 
14b in a 3:2 ratio (based on IH NMR). The mixture of 14a and 14b was used in the 
Horner-Wittig reaction without separation. Only 14a was coupled with aldehyde 13 in the 
Horner-Wadsworth-Emmons reaction to give the triene product 15. The reason for this 
selectivity is probably due to the fact that 14a is less sterically hindered than 14b so it is 
selectively consumed in the reaction. n-Butyl lithium was first used as the base to 
deprotonate 14a to generate the corresponding ylide, as described by Prestwich. However 
it only gave a poor yield (- 20 %). We presumed that n-butyl lithium was consuming 
most of the aldehyde before it coupled with the ylide. Therefore we tried less 
nucleophilic bases, such as potassium t-butoxide and LHMDS; the later one gave an 
excellent yield (84 %). 
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OHC~OEI ethylene glycol, O~C02El DIBAL-H, OD C PPTS 
CO 82 % 90 % 
10 
~OH TBDMS-Cl, O~OTBDMS imidazole p-TsOH 
Co 70 % Co 90 % 
11 12 
H~OTBDMS 
o 
13 
LiHMDS, 14a, 14b 
ODC 
86 % 
MeO~OTBDMS 
o 
15 
DIBAL-H, I I Mn02 
ODC HO~OTBDMS 
95 % 83 % 
16 
H~OTBDMS n-BuLi,18 OTBDMS 83 % 
o 17 19 
TBAF 
80 % OH 
9 
+ 
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Scheme 7 Synthesis of alcohol 9. 
Subsequent reduction of ester 15 with DIBAL-H at 0 DC gave alcohol 16 (88 %), which 
was then oxidized by active Mn02 to yield aldehyde 17 (80 %). We also examined the 
use of Dess-Martin reagent in this oxidation step, which gave a similar yield (76 %). 
Considering the ease of use and the lower cost, we chose Mn02 as the oxidizing reagent 
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in the end. The resulting aldehyde 17 was coupled with Wittig salt 18, which was derived 
from 1-bromo-3-methylbut-2-ene (Scheme 8), to give pentaene 19. Deprotection of the 
silyl ether gave pentaenol 9. However, all our efforts to transform the pentaenol 9 to its 
NBS, CCI4, 24 h 
60% 
triethylphosphite, 
reflux, 5 h 
85 % 
• 
CH30H, cone. H2S04, 
20h 
• 
98 % 
20 
lC~~ 
21b Sr 21a 
(EK)I,oP~CO,M' + 
14a 
tributyl phosphine, 
toluene, reflux 
91 % 
l~M' 
PO(OEt)2 
14b 
Scheme 8 Synthesis of phosphonate ester 14a, 14b and Wittig salt 18. 
Wittig salt failed. Treatment of alcohol 9 with halogenation reagents, such as HBr, PBr3, 
or CBr4 and PPh3, followed by reacting with PPh3 or PBU3, did not provide the desired 
phosphonium salt. Treatment of alcohol 9 with triphenylphosphine hydrobromide only 
gave a very poor yield (10 %) despite the results of Furuhata et al. who reported a one-
pot Wittig reaction which used a similar conjugated allylic alcohol as starting material. I 16 
In our case treatment of alcohol 9 with triphenylphosphine hydrobromide followed by 
adding aldehyde 6 and KOH in methanol gave no condensation product. In all our efforts 
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only aldehyde 6 was recovered. We believed that the bromide 8 or the phosphonium salt 
7 was too labile and that they decomposed quickly before they could be treated with a 
base, although reports on the instability of Wittig salts with a conjugated polyene system 
are rare. We also considered the possibility of switching the moiety bearing the 
phosphonium salt. However the Trolox bromide derived from Trolox® did not even react 
with triphenylphosphine, even when refluxed in toluene for 5 days (Scheme 9), 
presumably due to the sterically congested nature of this position. 
TBDMSO 
DffiAL-H, OOC 
23 24 
TBDMSO TBDMSO 
Br----iX~-
25 26 
Scheme 9 Synthesis of Trolox phosphonium salt. 
2.2.2.3 Synthesis of Compound 1 using C14 + CIO + Cs Strategy 
Instead of coupling the Trolox aldehyde 6 with Wittig salt 7, the aldehyde 6 was coupled 
with Wittig salt 28 first, with the rationale that by lacking one conjugated double bond it 
will be more stable than its pentaene analogue 7 (Scheme 11). 
Deprotection of silyl ether 15 by TBAF in THF gave alcohol 27 (65 %). However, the 
conversion of alcohol 27 to bromide 28 was not efficient. Several bromination reagents 
were used such as hydrobromide acid solution, PBr3 and CBr4 with PPh3, but the best 
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yield was only 40 %. When directly treated with triphenylphosphine hydrobromide, 
alcohol 27 was successfully converted to Wittig salt 28 with excellent yield (88 %). The 
Wittig salt was then deprotonated by LHMDS to give the corresponding ylide that was 
coupled with aldehyde 6 to give ester 29. Reduction of ester 29 with DffiAL-H at 0 °C 
afforded 30 (70 %), which was oxidized by active Mn02 to yield all-trans aldehyde 31, 
that was used in the next Wittig reaction. 
HO 
TBDMSO 
CH30H, p-TsOH 
reflux 
88 % 
TBDMSO 
DffiAL-H, -60 °C 
Scheme 10 Synthesis of trolox aldehyde 6. 
6 
TBDMSCI, 
imidazole. 8SoC 
The synthesis of aldehyde 6 followed the protocols reported by our group 11 7 (Scheme 10). 
First, the carboxylic acid group was converted to its methyl ester 22 by refluxing in 
DCMlmethanol which was catalyzed by p-toluenesulfonic acid monohydrate. Protection 
of the phenol group as a silyl ether was followed by reduction with DffiAL-H at -60 °C to 
give aldehyde 6 as a white solid. The reaction temperature was carefully controlled to not 
be higher than -60 - -55 °C otherwise most of the starting material would be reduced 
directly to the alcohol. 
The final Wittig reaction took place between aldehyde 31 and Wittig salt 18. n-Butyl 
lithium was used to generate the corresponding ylide at 0 °C then aldehyde 31 was added 
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at -78°C. Compound 32 was obtained with an excellent yield (87 %). Deprotection of 
silyl ether by TBAF in THF afforded the final product 1. 
TBDMSO~C02Me 
15 
TBAF 
68 % 
(Ph):;~C02Me 
28 
OH 
30 
.# .# CHO 
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LHMDS, aldehyde 6 
-78 DC 
40 % 
71 % 
MnOz 
39 % 
n-butylithium, 18 
-78 DC 
88 % 
TBAF 
38 % 
Scheme 11 Synthesis of compound 1 using C14 + CIO + C5 strategy. 
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2.3 Fluorescent Characterization of (l-Tocohexaenol. 
a-Tocohexaenol fluoresces in both ethanol and hexanes, with a maximum absorption at 
368 nm in ethanol and 367 nm in hexanes (Figure 10 & 11). The absorption coefficients 
are 43000 ± 1075 M-1 cm-1 in ethanol and 28000 ± 700 M-1 cm-1 in hexane respectively. 
The maximum emission of a-tocohexaenol is 521 nm with excitation at 366 nm (Figure 
12). 
The fluorescence intensity decreased significantly in aqueous solution. When the H20 content 
reached 90 % (v/v), the fluorescence of a-tocohexaenol showed a 7-fold decrease (Figure 13). 
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Figure 10. UV-Vis absorption of a-tocohexaenol in ethanol (concentration: 9.2 IlM). 
35 
0.25 
0.2 
c 
0 0.15 
:0:; 
Co 
... 
0 
1/1 0.1 .0 
<C 
0.05 
0 
310 330 350 370 390 410 
Wavelenth [nm] 
Figure 11. UV-Vis absorption ofa-tocohexaenol in hexane (concentration: 9.2 JlM). 
alpha-tocohexaenol 
2250000 -- ~------ - ---------.:-------- ----------.----!~ ----l-----------------f-------- --- ---------- ---------------l-----------------
.. . 
. , , . . , 
2000000 -- :- ------ ----------r---------- ---- ----f- ---------------(-- --In-ettiaAof---------+----------------t------------ --- --
. . 
1750000 ------- .. ...:...-----------------..: .. ------------- ----..:-------- ------,----
1500000 
~ 
"-1250000 
~ 
81000000 
750000 
500000 
- . . . _ ~~'a...l 
- : : : : : : -....: , , , . , 
0 - - : ; : ; . ; : : . ' . : ; ; i ; ; ; : i : . . :i : ; . ; , , : : ; 
400 450 500 550 600 650 700 
Wavelength [nmJ 
Figure 12. Fluorescence emission of a-tocohexaenol III ethanol & hexane 
(concentration: 4.6 JlM). 
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2.4 Stability Study of a-Tocohexaenol in Solution 
Conjugated polyenes such as lycopene1l8 are known to be susceptible to temperature, 
light, and air oxidation. Any future use of a-tocohexaenol as a biological probe for a-
tocopherol will require the knowledge of how to handle and store it to preserve its 
structural integrity. 
a-Tocohexaenol can be stored in the dark and at -10 °C for about one month without any 
significant changes in its UV absorption spectrum. It is relatively stable in ethanol and 
hexane if stored at low temperature (0 °C) and protected from light. The UV -Vis 
absorption spectrum showed no significant changes with a maximum absorption at 368 
nm in ethanol and 367 nm in hexanes after 10 days storage at 0 °C and protected from 
light. 
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2.4.2 Stability against UV and Light 
To test the stability of a-tocohexaenol against light, the solution of a-tocohexaenol in 
ethanol was prepared in a glass vial without cap and exposed under a TLC visualization 
UV lamp (254 nm) for 1 h, and the UV -Vis absorption spectrum was monitored. There 
was no change in the UV -Vis absorption spectrum. Then the solution of a-tocohexaenol 
was put on the bench top under room light and the UV -Vis absorption spectrum was 
monitored again. After 4 hours its maximum absorption wavelength shifted from 368 nm 
to 366 nm, and its maximum absorption decreased from 0.427 at 368 nm to 0.344 at 366 
nm (Figure 17). The TLC showed that little of the starting material (Rf = 0.45, 
hexane/ethyl acetate 3: 1) was left, and some new spots appeared: Rf = 0.58 (minor), Rf = 
0.31 (minor), Rf = 0.25 (major), and Rf = 0.19 (minor). It is well known that light can 
initiate isomerization of polyenes.l18 There are 32 possible trans-cis isomers of a-
tocohexaenol. Considering that cis-isomers are less stable than the all-trans isomer, 
mono-cis isomers will dominate after photoisomerization of all-trans a-tocohexaenol. 
Since the cis-isomer of an unmethylated double bond is unstable because of the steric 
interaction on the concave side of the cis bend,119 the main spot on TLC (Rf = 0.25) was 
probably the 3-cis or 7-cis isomer. When a cis double bond is introduced to an all-trans 
conjugated system such as carotene, the effective conjugation will be decreased and the 
UV absorption shifts to the blue. 120 This also explains the observed changes in the UV 
spectrum of a-tocohexaenol after light irradiation (Figure 15). 
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Figure 15. UV -Vis absorption of a-tocohexaenol in ethanol after exposed under room 
light. 
2.4.3 Stability under Acidic Condition 
A solution of a-tocohexaenol in ethanol was acidified by p-TsOR monohydrate (final 
concentration of p-TsOR monohydrate was 0.042 M) and the UV -Vis absorption 
spectrum and TLC was monitored. The color of the solution changed very quickly from 
yellow to pink after the acid was added. The UV -Vis absorption spectrum totally changed 
3 hour later (Figure 16), and the TLC showed that there was no a-tocohexaenol left and 
many more polar spots could be observed. 
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3. Conclusion and Future Work 
The synthesis of a-tocohexaenol, a fluorescent analogue of a-tocopherol, has been 
successfully completed and reported in this thesis. a-Tocohexaenol has a maximum 
fluorescence emission at 521 nm when excited at 366 nm and so should not be interfered 
with by endogenous fluorophores such as trytophan. It is stable in solution for two weeks 
if stored in the dark at low temperature (0 °C). If stored at room temperature and exposed 
to light, it will decompose within 5 hours. Thus, a-tocohexaenol may be a useful probe in 
the study of vitamin E if handled appropriately. This analogue has the highest structural 
similarity to a-tocopherol compared to other fluorescent analogues that have been 
reported. Upon the successful synthesis of this molecule, the first bioassay would be the 
measurement of the binding affinity with a-TTP. The new molecule is likely not to show 
the same affinity as a-tocopherol because it has a more rigid tail; but since the protein 
binds the vitamin with the chromanol buried and the tail partially escaping the active 
site,121 we suspect that it will still bind well enough with a-TTP for use in vitro assay. 
The next important assay would be the test of its ability as an antioxidant in vitro. We are 
looking forward to see the results of these assays in the very near future. 
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4. Experimental 
General 
All reagents were purchased from Sigma-Aldrich Chemical Co., Oakville, Ontario. All 
glassware was dried in an oven of 90 'c overnight, and then cooled in desiccators before 
use. Cooling baths were prepared with acetone/liquid nitrogen for -78 'c and -60 'c, and 
ice/water for 0 'c. Air or moisture sensitive reactions were performed under N2. THF 
(tetrahydrofuran) was distilled with sodium!benzonephenone immediately before use; 
benzene was distilled over sodium metal; dichloromethane was distilled over CaR2; 
methanol was distilled from Mgliodine. n-Butyllithium was titrated with diphenylacetic 
acid or N-benzylbenzamide to a yellow or a blue endpoint, respectively, right before use. 
Reagent grade solvents were used for extractions. Distilled water was used for all 
aqueous workups. 
Analytical thin-layer chromatography (TLC) was performed on Merck 0.25 mm pre-
coated silica gel 60 A F-254 aluminum plates and visualized under UV light, or stained in 
5 % KMn04 solution. Column chromatography was carried out on silica gel (200 - 300 
mesh) purchased from Aldrich. 
Optical rotations were recorded on a Rudolph Autopol TIl polarimeter. Fourier transform 
infrared spectra (FT-IR) were recorded on a Bomem MB-lOO spectrometer and the 
resonance frequency is reported in cm-I. IH-NMR and l3C-NMR spectra were measured 
on a Bruker Advance DPX-300 digital FT-NMR spectrometer (300 and 75 MHz, 
respectively) in CDCh with residual chloroform as internal reference (7.281 ppm for IH 
and 77.0 ppm for l3C) unless otherwise noted. Chemical shifts are reported as 8 values 
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and coupling constants (1) are reported in Hertz (Hz). The following abbreviations are 
used: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br (broad). Mass 
spectra (MS) were recorded on a Carlo ErbaiKratos GCIMS Concept IS double focusing 
mass spectrometer interfaced to a Kratos DART acquisition system and a Sun SPARC 
workstation. Samples were introduced through a direct inlet system. Ions are generated 
using electron impact (EI) or Fast Atom Bombardment (FAB) and were reported in rnIz 
values. Fluorescence were recorded on a Photon Technologies International 
QuantaMaster Model QM-2001 L-format, equipped with double-grating 
monochromators, a 150 W xenon lamp, and Felix 32 software. 
Synthesis of (E)-ethyl-3-(1,3-dioxolan-2-yl)but-2-enoate (10) 
A mixture of 3-methyl-4-oxo-but-2-enoic acid ethyl ester (14 ml, 92 mrnol) , ethylene 
glycol (8.75 mI, 140 mrnol), and PPTS (2.6 g, 10 mrnol) in benzene (200 mI) was heated 
to reflux under a Dean-Stark trap for 4 h. Upon cooling, water was added, and the 
aqueous layer was extracted with ether (3 x 50 mI). The combined organic layer was 
dried over anhydrous MgS04 and concentrated. The residue was purified on Si02 (ethyl 
acetate/hexanes 1:9) to give 16 g (90 %) of colorless oil. 
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TLC Rf = 0.4 (hexane/ethyl acetate = 9: 1) 
IH-NMR o 6.03 (s, 1H, =CH), 5.21 (s, 1H, OCHO), 4.20 (q, J = 7.2 Hz, 
J = 7.2 Hz, 3H, CH3). 
13C_NMR o 166.29, 152.59, 118.50, 105.12,65.43,60.00,14.24,13.16. 
Mass Spectra [EI+] rnJz 186 (M+, 1.3%), 157 (12.2%), 141 (22.3%), 113 (24.3%), 
73 (100%). 
Synthesis of (E)-3-(1,3-dioxolan-2-yl)-but-2-en-l-01 (11) 
Ester 10 (11.72 g, 63 mmol) in ether (50mI) was added to a solution of LiAIH4 (75.6 mI, 
75.6 mmol) in ether (120 mI) at 0 0c. The resulting suspention was stirred for 45 min 
before being quenched with methanol and H20. The aqueous layer was extracted with 
ethyl ether (4 x 60 mI) and the combined organic layers were dried over anhydrous 
MgS04 and concentrated. Purification on Si02 (ethyl acetatelhexanes 1: 1) afforded 7.44 
g (82 %) of alcohol as colorless oil. 
TLC Rf = 0.27 (hexane/ethyl acetate = 1: 1) 
IH-NMR 05.86 (t, J = 6 Hz, 1H, =CH), 5.13 (s, 1H, CH), 4.26 (d, J = 6.3 
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Mass Spectra [EI+] 
HRMS 
Hz, 2H, CH20), 4.09 (m, 4H, OCH2CH20), 1.67 (s, 3H, CH3). 
13C-NMR (75 MHz, CDCh) 
8 142.62, 139.22, 119.77, 112.16,65.41,63.68,9.59. 
rnJz 143 (M+, 1.7%), 113 (58.8%),73 (100%),45 (29.9%) 
Calcd: 143.07082, found: 143.07125. 
Synthesis of (E)-3-(1,3-dioxolan-2-yl)-but-2-enyloxy-(tert-butyldimethylsilyl)-ether 
(12) 
Imidazole (1.43 g, 21 mmol) and tert-butyldimethylsilyl chloride (3.16 g, 21 mmol) were 
added sequentially to a solution of alcohol 11 (2.9 g, 20 mmol) in DMF (60 ml). After 
stirring at room temperature for 2 h, water was added and the mixture was extracted with 
hexanes (4 x 30 ml). The combined organic extracts were dried over anhydrous MgS04 
and concentrated. Purification on Si02 (ethyl acetatelhexanes I :9) afforded 2.98 g (70 %) 
of oil. 
TLC Rf = 0.4 (hexane/ethyl acetate = 9: 1) 
IH-NMR 85.79 (t, J = 6 Hz, 1H, =CH), 5.13 (s, 1H, OCHO), 4.29 (d, J = 
6 Hz, 2H, CH20), 4.07 (m, 4H, OCH2CH20), 1.63 (s, 3H, CH3), 
0.88 (s, 9H, 3CH3), 0.07 (s, 6H, 2CH3). 
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Mass Spectra [EI+] 
HRMS 
o 132.49, 131.90, 106.89, 65.34, 59.87, 25.92, 18.32, 10.39, -
5.18. 
m1z 258 (M+, 0.6%), 83 (100%),75 (92.3%),73(39.6%). 
Calcd: 258.16512, found: 258.16569. 
Synthesis of 4-(tert-butyldimethylsilanyloxy)-2-methyl-but-2-enal (13) 
OHC~OTBDMS 
To a solution of compound 12 (2.93 g, 11 mmol) in acetone (120 ml) were added p-
toluene sulfonic acid monohydrate (211 mg, 1.11 mmol) and water (2.93 ml). The 
resulting solution was stirred for 10 min. Addition of a cold saturated aqueous NaHC03 
solution was followed by extraction with chloroform (4 x 60 ml). The combined organic 
extracts were washed with water and brine, dried over anhydrous MgS04 and 
concentrated. Purification on Si02 (ethyl acetate/hexanes 1 :9) afforded 2.28 g (90 %) of 
oil. 
TLC 
IH-NMR 
13C-NMR 
Rf = 0.4 (hexane/ethyl acetate = 9: 1) 
09.44 (s, 1H, CHO), 6.56 (t, J = 1.2 Hz, 1H), 4.53 (d, J = 6 Hz, 
2H, CH20), 1.74 (s, 3H, CH3), 0.94 (s, 9H, 3CH3), 0.12 (s, 6H, 
2CH3). 
o 194.60, 153.14, 138.00,60.50,25.84,25.65,9.38, -5.29. 
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Mass Spectra [EI+] rnlz 214 (M+, 2.2%),171 (10.1%), 157 (16.8%), 75 (100%). 
Synthesis of 8-(tert -butyldimethylsilanyloxy -2,6-dimethyl-octa -2,4,6-trienoic acid 
methyl ester (15) 
OTBDMS 
To a solution of a mixture of phospho nate ester 14a and 14b (6.75 g, 27 mmol) in dry 
THF (100 rnl) was added LHMDS (27 rnl, 1M in THF) at 0 'CO After stirring for 30 min, 
aldehyde 8 (1.89 g, 8.83 mmol) in THF (80 rnl) was added dropwise. After 3 h, the 
reaction was quenched by water and extracted with ethyl acetate (4 x 50 rnl). The 
combined organic extracts were dried over anhydrous MgS04 and concentrated. 
Purification on Si02 (ethyl acetate/hexanes 1 :9) afforded 2.36 g (86 %) of light yellow 
oil. 
TLC 
IH-NMR 
Mass Spectra [EI+] 
Rf = 0.4 (hexane/ethyl acetate = 9: 1) 
8 7.15 (d, J = 10 Hz, IH), 6.46 (d, J = 1.2 Hz, 3H, CH3), 1.73 
(d, J = 1.2 Hz, 3H, CH3), 0.83 (s, 9H, 3CH3), 0.0 (s, 6H, 2CH3). 
8 168.94, 143.67, 138.84, 135.92, 134.05, 126.24, 122.71, 
60.39,51.79,25.94, 18.38, 12.79, 12.61, -5.14. 
rnlz 310 (M+, 6.2%), 253 (46.9%),221 (49.1 %),178 (58.9%), 
147 (71.5%),119 (73.9%), 73 (100%). 
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HRMS Calcd: 310.19642, found: 310.19487. 
Synthesis of 8-(tert-butyldimethylsilanyloxy )-2,6-dimethyl-octa-2,4,6-trien-l-o1 (16) 
HO 
OTBDMS 
To a solution of ester 15 (1.85 g, 5.96 mmol) in THF (40 rnI) was added DIBAL-H (12.5 
rnI, 1 M solution in THF) at 0 0c. After stirring for 2 h, the reaction was quenched with 
methanol and water, followed by extraction with ethyl acetate (4 x 30 rnI). The combined 
organic extracts were dried over MgS04 and concentrated. Purification on SiOz (ethyl 
acetateihexanes 1 :2) afforded 1.60 g (95 %) of oil. 
TLC 
lH-NMR 
Mass Spectra [EI+] 
HRMS 
Rf = 0.4 (hexane/ethyl acetate = 2: 1) 
o 7.4 (m, IH, =CH), 6.5-6.0 (m, 2H, =CH), 5.5 (t, J = 5.2 Hz, 
lH, =CH), 4.16 (d, J = 6.4 Hz, 2H, CHz), 3.97 (s, 2H, CHz), 
1.59 (s, 3H, CH3), 1.47 (s, 3H, CH3), 0.83 (s, 9H, 3CH3), 0.0 (s, 
6H,2CH3). 
o 137.05, 137.00, 134.42, 131.95, 125.50, 123.26,68.66,60.37, 
25.98,18.40,14.31, 12.67, -5.09. 
mlz 282 (M+, 1.7%), 133 (18.3%),93 (21.4%),75 (100%). 
Calcd: 282.20151, found: 282.20077. 
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Synthesis of 8-(tert-butyldimethylsilanyloxy)-2,6-dimethyl-octa-2,4,6-trienal (17) 
OHC OTBDMS 
A mixture of alcohol 16 (1.82 g, 6.44 mmol), Mn02 (10.16 g, 116.86 mmol) and Na2C03 
(3.42 g, 32.27 mmol) in DCM was stirred overnight at room temperature. After filtration 
and concentration, the residue was purified on Si02 (ethyl acetatelhexanes 1:3) to give 
1.50 g (83 %) of yellow oil. 
TLC 
IH-NMR 
Mass Spectra [EI+] 
HRMS 
Rf = 0.48 (hexane/ethyl acetate = 3: 1) 
8 9.36 (s, IH, CHO), 6.81 (dd, h = 1.2 Hz, h = 10.4 Hz, IH, 
=CH), 6.61-6.52 (m, 2H, =CH), 5.77 (t, J = 1.2 Hz, IH, =CH), 
4.29 (d, J = 6 Hz, 2H, OCH2), 1.79 (d, J = 1.2 Hz, 3H, CH3), 
1.75 (d, J = 1.2 Hz, 3H, CH3), 0.83 (s, 9H, 3CH3), 0.0 (s, 6H, 
2CH3). 
8 195.0, 149.3, 145.8, 138.1, 134.1, 122.6, 60.6, 33.6, 26.1, 
18.6, 12.8,9.8, -4.9. 
rnlz 280 (M+, 2.4%), 223 (11.7%),148 (19.8%), 75 (100%). 
Calcd: 280.18586, found: 280.18541. 
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Synthesis of 1-(tert-butyldimethylsilanyloxy )-3, 7 ,ll-trimethyl-dodeca-
(2E,4E,6E,8E,10E)-2,4,6,8,10-pentaene (19) 
OTBDMS 
To a suspension of tributyl isoprenyl phosphonium bromide 18 (1.57 g, 4.47 mmol) in 
dry THF (95 rnl) was added n-BuLi (2.8 rnl, 4.48 mmol, 1.6 M in THF). After stirring at 
o °C for 30 min under N2, the solution was cooled to -78°C. The aldehyde (502 mg, 1.79 
mmol) in THF (10 rnl) was added dropwise. The reaction was allowed to warm up to 
room temperature and stirred overnight. It was quenched with water and extracted with 
ethyl acetate (4 x 40 rnl). The combined organic extracts were dried over anhydrous 
MgS04 and concentrated. Purification on Si02 (ethyl acetatelhexanes 1:9) afforded 496 
mg (83 %) of orange oil. 
TLC 
IH-NMR 
13C-NMR 
Rf = 0.65 (hexane/ethyl acetate = 9: 1) 
() 6.52 (m, 2H, =CH), 6.32 (m, 3H, =CH), 5.96 (d, J = 12Hz, 
IH, =CH), 5.63 (t, J = 6.3 Hz, IH, =CH), 4.37 (d, J = 6 Hz, 2H, 
OCH2), 1.96 (s, 3H, CH3), 1.83 (s, 9H, 3CH3), 0.92 (s, 9H, 
3CH3), 0.09 (s, 6H, 2CH3). 
() 136.83, 135.75, 135.64, 134.93, 134.80, 131.93, 125.97, 
124.66, 124.42,60.44,26.27, 26.00, 25.98, 18.56, 18.54, 12.84, 
12.64, -4.9. 
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Mass Spectra [EI+] mlz 332 (M+, 3.1%), 200 (13.1%),117 (28.1%), 84 (71.6%), 
75 (100%). 
Synthesis of 3, 7 ,1l-trimethyl-dodeca-(2E,4E,6E,8E,10E)-2,4,6,8,10-pentaen-l-ol (9) 
OH 
To a solution of compound 19 (355 mg, 1.07 mmol) in THF (50 mI) was added TBAF 
(10.7 mI, 1 M in THF) at room temperature. After stirring for 4 h, the reaction was 
quenched with water and extracted with ethyl acetate (4 x 10 mI). The combined organic 
extracts were dried over anhydrous MgS04 and concentrated. Purification on Si02 (ethyl 
acetate/hexanes 1:3) afforded 186 mg (80 %) of orange solid. 
TLC 
M.P. 
IH-NMR 
13C_NMR 
Mass Spectra [EI+] 
Rf = 0.18 (hexane/ethyl acetate = 3: 1) 
108-110 'c. 
() 6.61 (m, 2H, =CH), 6.33 (m, 3H, =CH), 5.73 (d, J= 11.1 Hz, 
1H, =CH), 5.71 (t, J = 7.2 Hz, 1H, =CH), 4.31(t, J = 6 Hz, 2H, 
OCH2), 1.96 (s, 3H, CH3), 1.88 (s, 3H, CH3), 1.83 (s, 6H, 
2CH3). 
() 136.85, 136.41, 136.25, 135.85, 134.83, 130.68, 130.25, 
125.97, 125.23, 124.93,59.46,26.26, 18.56, 12.86, 12.61. 
mlz 218 (M+, 16.8%),200 (42.3%),145 (42.9%), 105 (46.4%), 
52 
91 (51.9%),43 (100%). 
HRMS Calcd: 218.16707, found: 218.16680. 
Synthesis of 2-methyl-but-2-enoic acid methyl ester (20) 
A mixture of tiglic acid (20.23 g, 0.2 mol), methanol (100 ml) and 100 drops of conc. 
H2S04 was heated at reflux for 20 h. After adding 100 ml water, it was extracted with 
DCM (100 ml x 2). The organic layer was washed with dilute NaHC03 solution, dried 
over anhydrous MgS04 and distilled under vacuum to afford 22.6 g (98 %) of colorless 
oil (56-65 °C/30 mm Hg). 
IH-NMR 
13C-NMR 
Mass Spectra [EI+] 
HRMS 
8 6.90 (dd, h = 7 Hz, h = 2.0 Hz, IH, =CH), 3.71 (s, 3H, 
OCH3), 1.84 (s, 3H, CH3), 1.81 (d, J = 8 Hz, 3 H, CH3). 
8 168.60, 137.18, 128.47,51.61,14.29, 12.00. 
mlz 114(M+, 52.1 %),83(57.3%),55(100%),43(53%). 
Calcd: 114.06808, found: 114.06811. 
Synthesis of 4-bromo-2-methyl-but-2-enoic acid methyl ester and 2-bromomethyl-
but-2-enoic acid methyl ester (21a, 21b) 
53 
A mixture of compound 20 (10 g, 87.5 mmol) and NBS (17.25 g, 97.5 mmol) in CC4 
(100 ml) was heated at reflux for 14 h. After filtration and concentration, it was purified 
on Si02 (DCM) to give 10.1 g (60 %) of a mixture of E and Z isomers (E/Z = 2: 1). 
TLC Rf = 0.65 (DCM) 
IH-NMR 8 7.13 (m, J = 7.5 Hz, 1H, =CH), 6.94 (m, J = 6.8 Hz, 1 H, 
=CH), 4.25 (s, 2H, CH2Br), 4.03 (d, J = 8.4 Hz, 2H, CH2Br), 
3.81,3.79 (2s, 6H, 2CH3), 1.95 (m, 2CH3). 
Mass Spectra [EI+] mlz 193 (M+, 50.1%),191 (41.5%), 113 (100%), 82 (25.2%), 
53 (32.3%) 
HRMS Calcd: 191.97859, found: 191.97845. 
Synthesis of 4-(diethoxy-phosphoryl)-2-methyl-but-2-enoic acid methyl ester (14a, 
14b) 
54 
A mixture of compound 21a and 21b (8 g, 41.2 mmol) and triethylphosphite (7.2 ml, 41.4 
mmol) was heated at reflux for 5 h. After concentrated under vacuum, it was purified on 
Si02 (ethyl acetate/methanol 9:1) to give 8.71 g (85 %) of phosphate (E/Z = 3:2). 
TLC Rf = 0.22 (ethyl acetate/methanol = 9: 1) 
86.77 (m, 1H, =CH), 6.41 (d, J = 5.7 Hz, 1H, =CH), 5.91 (d, J 
= 5.1 Hz, 1H, =CH), 4.17 (m, 4H, 2POCH2), 3.78, 3.75 (2s, 6H, 
2CH3), 2.80 (dd, h = 8.8 Hz, h = 23.4 Hz, PCH2), 3.50-3.34 
(dd, 11 = 8 Hz, 12 = 24 Hz, 2H, PCH2), 1.94 (d, 1 = 3.04 Hz, 3H, 
Mass Spectra [EI+] m1z 250 (M+, 42.6%), 190 (36.0%),162 (50.2%), 109 (57.1 %), 
81 (100%). 
HRMS Calcd: 250.09701, found: 250.09639. 
Synthesis of tributyl-(3-methyl-but-2-enyl)-phosphonium bromide (18) 
A mixture of tributyl phosphine (2 ml, 17.2mmol) and 4-bromo-2methyl-2-butene (4.25 
ml, 17.2 mmol) in toluene (30 ml) was heated at reflux for 5 h. After the toluene was 
removed by vacuum, hexanes (60 ml) was added and the solution was heated at reflux for 
55 
1 h. After cooled to room temperature the solid was filtered and dried under vacuum to 
give a white crystal (5.48 g, 91 %). 
M.P. 
IH-NMR 
Mass Spectra [FAB] 
61-63 'c. 
8 4.99 (m, =CH), 3.40 (q, J = 7.8 Hz, 2H, CH2P), 2 . .49-2.34 
(m, 6H, 3CH3) 
8 109.08, 108.96, 24.01, 23.81 , 23.75, 23 .68, 19.19, 18.57, 
13.41. 
rnlz 271(M-Br, 100%) 
Synthesis of (S)-6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid methyl 
ester (22) 
To a solution of (S)-trolox (1.00g, 2.01 mmol) in 100 rnl of DCM and methanol (1: 1) was 
added p-toluene sulphonic acid (0.40 g, mmol). The resulting solution was heated at 
reflux for 18 h. Water was added and the aqueous layer was extracted with chloroform (3 
x 20 rnl). The combined organic layers were washed with water and brine, dried over 
Mg2S04, and concentrated. Purification on Si02 (DCMlmethanol 10: 1) afforded 0.94 g 
white solid (88%). 
56 
TLC 
M.P. 
IH-NMR 
13C_NMR 
Mass Spectra [EI+] 
Rf= 0.65 (DCMlmetahnol = 10:1) 
134-136 "C 
8 3.69 (s, 3H, OCH3), 2.65 (m, 2H, CH2), 2.47 (m, IH, CH2), 
2.20 (s, 3H, CH3), 2.18 (s, 3H, CH3), 2.08 (s, 3H, CH3), 1.91 
(m, IH, CH2), 1.62 (s, 3H, CH3). 
8 174.47, 145.53, 121.21, 118.36, 116.89, 52.34, 30.61, 25.42, 
20.95, 12.20, 11.81, 11.24. 
rnJz 264 (M+, 77%), 205 (100%), 164 (76%). 
Synthesis of (S)-6-(tert-butyl dimethyl silyl-oxyl)-2,5,7,8-tetramethyl-chroman-2-
carboxylic acid methyl ester (23) 
C02Me 
To a solution of compound 22 (493 mg, 1.87 mmol) in anhydrous DMF (5 ml) was added 
imidazole (515 mg, 7.56 mmol) and TBDMS chloride (570 mg, 3.78 mmol). The mixture 
was heated to 85 "C and stirred under N2 overnight. After water was added, the mixture 
was extracted with ethyl acetate (4 x 25 ml). The combined organic layers were washed 
with water and brine, dried over MgS04 and concentrated. Purification on Si02 
(DCMlhexanes 3:1) afforded 700 mg (99 %) of colorless oil. 
57 
TLC 
lH-NMR 
Mass Spectra [EI+] 
R[= 0.53 (DCMlhexane = 3:1) 
() 3.68 (s, 3H, OCH3), 2.58 (m, 2H, CH2), 2.45 (m, 1H, CH2), 
2.16 (s, 3H, CH3), 2.12 (s, 3H, CH3), 2.03 (s, 3H, CH3), 1.90 
(m, 1H, CH2), 1.61 (s, 3H, CH3), 1.08 (s, 9H, 3CH3), 0.13 (s, 
6H, 2CH3). 
() 174.55, 144.81, 122.70, 117.05, 52.28, 30.57, 26.09, 25.38, 
21.05,18.61,14.31,13.37,11.89, -3.30, -3.36. 
rnIz 378 (M+, 8.9%),189 (24.8%), 147 (100%). 
Synthesis of (S)-6-(tert-butyldimethylsilanyloxy)-2,S,7,8-tetramethyl-chroman-2-
carbadehyde (6) 
CHO 
The solution of compound 23 (673 mg, 1.78 mrnol) in dry DCM (7.5 rnI) was cooled to -
60 'c. After 20 min DIBAL-H (2.14 ml, 1M in DCM) was added to this stirred solution. 
The mixture was stirred under N2 for 2 h. The reaction was quenched with methanol, and 
then the mixture was poured into water and extracted with ethyl acetate (3 x 30 rnI). The 
combined organic layers were washed with water and brine, dried over anhydrous 
58 
MgS04 and concentrated. Purification on Si02 (DCMlhexanes 3: 1) afforded 341 mg (55 
%) of white crystal. 
TLC 
M.P. 
IH-NMR 
Mass Spectra [EI+] 
Rf= 0.52 (DCMlhexane = 3:1) 
70-72 °C 
() 9.64 (s, 1H, CHO), 2.56 (m, 2H, CH2), 2.30 (m, 1H, CH2), 
2.18 (s, 3H, CH3), 2.16 (s, 3H, CH3), 2.12 (s, 3H, CH3), 1.84 
(m, 1H, CH2), 1.40 (s, 3H, CH3), 1.08 (s, 9H, 3CH3), 0.13 (s, 
6H,2CH3). 
8 204.81, 145.56, 145.15, 126.47, 123.86, 122.83, 117.61, 
80.26, 27.93, 26.08, 21.59, 20.48, 18.60, 14.34, 13.36, 12.04, -
3.31. 
rnIz 348 (M+, 42.2%),319 (33%), 277 (100%), 73 (56.3%). 
Synthesis of 8-hydroxy-2,6-dimethyl-octa-2,4,6-trienoic acid methyl ester(27) 
OH 
To a solution of compound 15 (2.23 g, 7.19 mmol) in THF (250 ml) was added TBAF 
(33 ml, 1 M in THF) under N2• After 4 h the reaction was quenched with water followed 
by extraction with ethyl acetate (4 x 50 ml). The combined organic extracts was dried 
over anhydrous MgS04 and concentrated. Purification on Si02 (hexanes/ethyl acetate 
1: 1) afforded 962 mg (68 %) of pale yellow crystal. 
59 
M.P. 58-60°C. 
TLC Rf = 0.27 (hexane/ethyl acetate = 9: 1) 
IH-NMR 8 7.28 (d, J = Hz, 1H, =CH), 6.55 (m, 2H, =CH), 5.84 (t, 1H, 
=CH), 4.37 (d, J = 6.6, 2H, CH2), 3.78 (s, 3H, CH3), 2.00 (s, 
13C_NMR 8 168.62, 143.29, 138.63, 135.92, 134.12, 126.74, 123.45, 
59.51,51.84,12.82, 12.58. 
Mass Spectra [EI+] mlz 210 (M+, %),196 (53.3%),119 (91.7%), 107 (96.3%),91 
(100%),41 (59.1 %). 
Synthesis of triphenyl-(2,6-dimethyl-octa-2,4,6-trienoic acid methyl ester)-
phosphonium bromide(28) 
The mixture of alcohol 27 (312 mg, 1.59 mmol) and triphenylphosphinehydrobromide 
(657 mg, 1.91 mmol) in DCM and ethyl ether (10 ml, 3:2) was stirred for 4 h at room 
temperature under N2. After the solvent was removed, the residue was washed with 
hexanes (5 x 10 ml), dried under vacuum to give 865 mg of orange foam, and it was used 
directly in next step without further purification. 
60 
M.P. 
IH-NMR 
Mass Spectra [FAB] 
HRMS 
122-124 'c 
o 7.18 (d, J = 9.6, 1H, =CH), 6.4 (m, 2H, =CH), 5.58 (m, 1H, 
=CH), 5.00 (m, 2H, PCH2), 3.73 (s, 3H, OCH3), 1.93 (s, 3H, 
CH3), 1.54 (d, J = 3.6 Hz, 3H, CH3). 
mlz 441 (M-Br), 100%),262(38.3%),55(58%). 
Calcd: 441.19834, found: 441.20047. 
Synthesis of (S)-6-(tert-butyldimethylsilanyloxy )-2,5, 7 ,8-tetramethyl- chroman-2( 4,8-
dimethyl-l,3,5,7-tetraenoic acid methyl ester) (29) 
C02Me 
To a solution of phosphonium bromide 28 (410 mg, 0.79 mmol) in THF (10 ml) was 
added LHMDS (0.27 ml, 0.27 mmol) at 0 'c under N2. The resulting red wine-like 
solution was stirred for 30 min, and was cooled to - 78 'C. The Trolox aldehyde 6 (92 
mg, 0.26 mmol) in THF (2 ml) was added through a syringe. The mixture was allowed to 
warm up to room temperature and stirred overnight. Water was added followed by 
extraction with ethyl acetate (4 x 20 ml). The combined organic extracts was dried over 
anhydrous MgS04 and concentrated. Purification on Si02 (DCMlhexanes 3: 1) afforded 
55.6 mg (40 %) oflight yellow oil. 
61 
TLC 
IH-NMR 
Mass Spectra [EI+] 
HRMS 
Rf= 0.42 (DCMlhexane = 3:1) 
87.29 (d, J = 12 Hz, IH, =CH), 7.09 (d, J = 12 Hz, IH, =CH), 
6.60 (m, 2H, =CH), 6.34 (t, J=12, IH, =CH), 5.59 (d, J=12 Hz, 
IH, =CH), 3.80 (s, 3H, CH3), 2.60 (m, 2H, CH2), 2.58 (m, IH, 
CH2), 2.19 (s, 3H, Ar-CH3), 2.11 (s, 3H, Ar-CH3)" 2.05 (s, 3H, 
Ar-CH3), 2.01 (s, 3H, CH3), 1.98 (m, IH, CH2), 1.88 (s, 3H, 
CH3), 1.56 (s, 3H, CH3), 1.05 (s, 9H, 3CH3), 0.13 (s, 6H, 
2CH3). 
8 168.99, 145.73, 144.47, 144.44, 139.04, 137.25, 135.89, 
130.73, 126.11, 125.69, 123.59, 123.24, 122.51, 117.68,75.98, 
51.81, 34.76, 33.73, 27.51, 25.29, 21.24, 18.60, 14.38, 13.43, 
12.84, 12.44, 11.88, -3.31. 
rn/z 510 (M+, 23.9%), 378 (23.1 %),319 (58.4%), 279 (42.3%), 
73 (100%). 
Calcd: 510.31645, found: 510.31621. 
Synthesis of (2E,4E,6E,8E)-9-( 6-(tert-butyldimethylsilanyloxy )-(S)-2,5, 7 ,8-
tetramethylchroman-2-yl)-2,6-dimethylnona-2,4,6,8-tetraen -1-01) (30) 
OH 
62 
To a solution of ester 17 (270 mg, 0.53 mmol) in THF was added DIBAL-H (1.6 ml, 1M 
in DCM) at 0 "C. The resulting solution was stirred for 2 h under N2. The reaction was 
quenched with methanol and water, followed by extraction with ethyl acetate (4 x 20 ml). 
The combined organic extracts were dried over anhydrous MgS04 and concentrated. 
Purification on Si02 (ethyl acetate/hexanes 1:3) afforded 180 mg (71 %) of oil. 
TLC 
IH-NMR 
13C-NMR 
Mass Spectra [EI+] 
HRMS 
R[= 0.33 (hexane/ethyl acetate = 3:1) 
8 6.91 (d, 1=12, IH, =CH), 6.49-6.28 (m, 3H, =CH), 6.20 (d, 
1=10.8, IH, =CH), 5.49 (d, 1=12, IH, =CH), 4.13 (m, 2H, OH-
CH2), 2.60 (t, 2H, CH2), 2.18 (s, 3H, CH3), 2.10 (s, 3H, CH3), 
2.05 (s, 3H, CH3), 1.98-1.85 (m, 8H, CH2 and 2CH3), 1.55 (s, 
3H, CH3), 1.05 (s, 9H, 3CH3), 0.13 (s, 6H, 2CH3). 
8 136.30, 135.29, 127.66, 127.40, 125.92, 125.76, 122.57, 
76.58, 69.40, 68.67, 63.18, 33.71, 27.83, 27.47, 27.05, 26.09, 
21.26, 21.06, 20.44, 20.37, 18.60, 14.32, 12.36, 12.01, -3.32, -
3.37. 
mlz 482(M+,4.05%), 86(81%), 84(100%). 
Ca1cd: 482.32162, found: 482.30629. 
Synthesis of (2E ,4E ,6E ,8E)-9-( 6-(tert -butyldimethylsilanyloxy )-(S)-2,5, 7 ,8-
tetramethylchroman-2-yl)-2,6-dimethylnona-2,4,6,8-tetraenal) (31) 
63 
CHO 
A mixture of alcohol 30 (180 mg, 0.38 mmol) , Mn02 (600 mg, 6.9 mmol) and Na2C03 
(200 mg, 1.89 mmol) in DCM (15 ml) was stirred for 3 h at room temperature. After 
filtration and concentration, the residue was purified on Si02 (ethyl acetate/hexanes 1 :3) 
to give 69 mg (39 %) of yellow oil. 
TLC 
IH-NMR 
Mass Spectra [EI+] 
HRMS 
Rf = 0.58 (hexane/ethyl acetate = 3: 1) 
() 9.49 (s, 1H, CHO), 7.18 (d, J = 12 Hz, 1H, =CH), 6.97 (d, J = 
9.6 Hz, 1H, =CH), 6.72-6.65 (m, 2H, =CH), 6.40-6.32 (t, J = 
12 Hz, 1H, =CH), 5.64 (d, J = 12 Hz, 1H, =CH), 2.60 (t, J = Hz, 
2H, CH2), 2.20 (s, 3H, CH3), 2.11 (s, 3H, CH3), 2.06 (s, 3H, 
CH3), 1.98-1.85 (m, 8H, CH2 and 2CH3), 1.56 (s, 3H, CH3), 
1.05 (s, 9H, 3CH3), 0.13 (s, 6H, 2CH3). 
() 193.61, 148.21, 145.37, 144.66, 143.45, 137.21, 135.73, 
135.98, 134.70, 131.88, 124.53, 122.67, 121.82, 121.33, 116.65, 
75.06, 59.35, 32.69, 26.46, 25.06, 20.20, 17.57, 13.37, 12.41, 
11.42, 10.84,8.61, -4.33. 
mlz 480 (M+, 21.6%), 221 (27.9%), 149 (39.7%), 95 (55.2%), 
73 (100%). 
Calcd: 480.30597, found: 480.30605. 
64 
Synthesis of tert-butyldimethylsilanyloxy ((S)-2,S,7,8-tetramethyl-2-
((lE,3E,SE,7E,9E)-4,8,12-tetramethyltrideca-l,3,S,7,9,1I-hexaenyl)chroman-6-
yoxyl)silane (32) 
To a solution of phosphonium salt 13 (160 mg, 0.46 mmol) in THF (12 ml) was added n-
BuLi (0.33 ml, 1.39 M in hexane) at 0 0c. The resulting pale yellow solution was stirred 
for 30 min under N2. The aldehyde 20 (81.7 mg, 0.17 mmol) in THF (2 ml) was added 
after the reaction mixture was cooled to -78°C. The mixture was allowed to warm up to 
room temperature and stirred overnight. Water was added followed by extraction with 
ethyl ether (4 x 15 ml). The combined organic extracts was dried over anhydrous MgS04 
and concentrated. Purification on Si02 (ethyl acetate/hexanes 1:9) afforded 79.3 mg (88 
%) of orange oil. 
TLC 
IH-NMR 
Rf = 0.67 (hexane/ethyl acetate = 9: 1) 
o 6.93 (d, J=12, 1H, =CH), 6.60-6.18 (m, 6H, =CH), 5.99 (d, 
J=10.8, 1H, =CH), 5.5(d, J=12, 1H, =CH), 2.60 (t, 2H, CH2), 
2.20 (s, 3H, CH3), 2.12 (s, 3H, CH3), 2.06 (s, 3H, CH3), 
1.98-1.85 (m, 14H, 1CH2 and 3CH3), 1.57 (s, 3H, CH3), 1.06 
(s, 9H, 3CH3), 0.14 (s, 6H, 2CH3). 
65 
Mass Spectra [EI+] 
HRMS 
8 ppm 145.88, 144.37, 137.70, 136.02, 135.74, 135.19, 134.99, 
131.29,127.44,126.07,125.11,124.80,123.54,122.62,117.80, 
75.96, 33.74, 27.52, 26.29, 26.12, 21.31, 18.62, 18.59, 14.38, 
13.44, 12.90, 12.38, 11.99, -3.30. 
rn/z 532 (M+, 9.5%), 319 (39.3%), 279 (30.5%), 221 (24.9%), 
91 (44.5%),73 (100%), 57 (50.2%),43 (83.8%). 
Calcd: 532.37366, found: 5323.37321. 
Synthesis of (S)-6-hydroxy-2,S,7,8-tetramethyl-2-((lE,3E,SE,7E,9E)-4,8,12-
tetramethyl-trideca-1,3,S, 7,9,1l-hexaenyl)chromane (1) 
To a solution of compound 32 (50 mg, 0.09 mmol) in THF (5 ml) was added TBAF (0.2 
ml, 1 Min THF) at room temperature under N2. After stirring for 2 h, the reaction was 
quenched with water and extracted with ethyl acetate (4 x 10 ml). The combined organic 
extracts were dried over anhydrous MgS04 and concentrated. Purification on Si02 (ethyl 
acetatelhexanes 1:3) afforded 14.3 mg (38 %) of compound 1 as an orange oil. 
TLC 
IH-NMR 
Rf = 0.45 (hexane/ethyl acetate = 3:1) 
8 6.92 (d, J=12, 1H, =CH), 6.63-6.22 (m, 6H, =CH), 5.97 (d, 
66 
Mass Spectra [EI+] 
HRMS 
1=10.8, 1H, =CH), 5.49(d, 1=12, 1H, =CH), 4.19 (b, 1H), 2.65 
(m, 2H, CH2), 2.22 (s, 3H, CH3), 2.17 (s, 3H, CH3), 2.11 (s, 3H, 
CH3), 1.98-1.85 (m, 14H, 1CH2 and 3CH3), 1.57 (s, 3H, CH3), 
0.93 (s, 9H, 3CH3), 0.12 (s, 6H, 2CH3). 
8 ppm 145.47, 144.84, 137.62, 136.92, 136.10, 135.81, 134.94, 
131.21, 127.25, 126.33 126.03, 125.19, 124.84, 121.13, 118.52, 
117.65,75.89,34.66,33.74,31.58,27.59,26.27,25.27,21.16, 
12.88, 12.23, 12.16, 12.00, 11.29. 
rnIz 418(M+, 1.6%),205(3.8%),149(13.6%),75(100%). 
calcd 418.28718, found 418.28669. 
67 
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